FDA Approves Zanvastro as First Targeted Treatment for Alexander Disease

The U.S. Food and Drug Administration (FDA) has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in children and adults. The approval represents a significant development for people living with this rare neurological disorder, as Zanvastro is the first FDA-approved treatment for Alexander disease.

The new therapy is also notable because it is designed to address an underlying biological mechanism associated with the disease rather than focusing only on managing symptoms. The approval gives patients and families a new treatment option for a condition that previously had no approved disease-targeted therapy.

What Is Alexander Disease?

Alexander disease is a rare and progressive neurological disorder associated with mutations in the GFAP gene, which provides instructions for producing glial fibrillary acidic protein. Abnormal GFAP can accumulate within cells that support the nervous system, contributing to progressive damage in the brain and other parts of the nervous system.

The condition is extremely uncommon, affecting fewer than one in a million people. Despite its rarity, Alexander disease can have a profound impact on patients and their families.

Symptoms and disease progression can vary considerably depending on the age at which the condition begins. Patients may experience seizures, developmental regression, difficulty walking, muscle weakness, problems with movement, and increased pressure inside the brain. In severe cases, the disease can become life-threatening.

Until now, treatment for Alexander disease has primarily focused on supportive care and management of individual symptoms. The FDA's approval of Zanvastro introduces a therapy intended to interfere with the biological process contributing to the disease.

How Does Zanvastro Work?

Zanvastro is an antisense oligonucleotide, a type of medicine designed to influence the production of specific proteins in the body.

In Alexander disease, mutations in the GFAP gene can lead to the production of abnormal GFAP protein. Zanvastro works by reducing the production of GFAP, with the goal of limiting the buildup of the abnormal protein that is associated with neurological damage.

This approach is particularly important because it targets a mechanism believed to play a central role in Alexander disease. Rather than simply addressing symptoms after they develop, the treatment is intended to reduce the production of the protein involved in the disease process.

Zanvastro is administered through an injection into the spinal canal, also known as an intrathecal injection. Treatment is given once every three months by a trained healthcare professional.

Clinical Evidence Behind the FDA Approval

The safety and effectiveness of Zanvastro were evaluated in a multicenter, randomized, controlled clinical study identified as NCT04849741. The study included 49 pediatric and adult participants with Alexander disease who were at least 2 years old.

An additional open-label substudy included four children younger than 2 years of age. Because Alexander disease is exceptionally rare and affects patients across a broad range of ages, collecting large clinical trial populations can be challenging.

For participants aged 5 years and older who had measurable walking difficulties when they entered the study, researchers evaluated walking speed. At 61 weeks, patients who received Zanvastro demonstrated significantly better walking speed compared with participants who did not receive the treatment.

Researchers used a different assessment for children between 2 and 4 years old. At this age, walking speed alone may not provide a reliable picture of neurological development. Instead, a broader measure of motor function was used, including abilities such as standing, walking, running, and jumping.

Children who received Zanvastro showed improvement on this measure, while children in the control group experienced a decline.

Zanvastro and Treatment for Infants

The FDA's approval also covers very young patients, including infants. However, direct clinical evidence in children younger than 2 years was more limited because Alexander disease is so rare and there was no concurrent control group for this age category.

To support the use of Zanvastro in younger patients, pharmacokinetic modeling was used to estimate how the medicine would behave in this age group. The modeling indicated that drug exposure in children younger than 2 years was expected to be comparable to exposure observed in older children receiving the same dose.

Safety information from four children under 2 years who participated in the study also contributed to the overall assessment. Together with safety data from older pediatric patients, these findings supported extending the treatment indication to infants.

Potential Side Effects of Zanvastro

As with any medical treatment, Zanvastro can cause side effects. The most commonly reported adverse reactions include:

• Vomiting
• Back pain
• Cough
• Headache
• Post-lumbar puncture syndrome

Patients and caregivers should also be aware that aseptic meningitis has been reported in people receiving Zanvastro.

Anyone receiving the treatment should promptly discuss concerning symptoms with their healthcare provider. Patients and caregivers should review the medicine's complete prescribing information with their medical team before starting treatment.

Why the Approval Matters for Rare Disease Patients

The FDA approval of Zanvastro is particularly significant because of the limited treatment options historically available for Alexander disease.

Rare neurological diseases often present major challenges for researchers and drug developers. Small patient populations can make it difficult to conduct traditional large-scale clinical trials, while the wide range of symptoms and ages affected by a disease can complicate the measurement of treatment outcomes.

Zanvastro's development received several FDA designations intended to support the development and review of therapies for serious and rare conditions. These included Orphan Drug, Fast Track, Breakthrough Therapy, Rare Pediatric Disease, and Priority Review Voucher designations.

The approval therefore represents not only a potential new treatment option for Alexander disease, but also an important milestone in rare disease drug development.

What the Zanvastro Approval Means for Patients

For individuals and families affected by Alexander disease, the availability of an FDA-approved treatment provides a new avenue for discussing disease management with specialists.

Because Alexander disease can differ substantially from one patient to another, treatment decisions should be made on an individual basis. Healthcare professionals can evaluate factors such as age, symptoms, disease progression, overall health, and potential treatment risks when determining whether Zanvastro may be appropriate.

The approval does not mean that every patient will experience the same response. Continued monitoring and medical follow-up will remain important for people receiving the therapy.

A New Chapter in Alexander Disease Treatment

The FDA's approval of Zanvastro marks a major milestone in the treatment of Alexander disease. As the first FDA-approved therapy for the condition, Zanvastro offers a disease-targeted approach based on reducing the production of GFAP.

While further experience with the treatment will help doctors and researchers understand its long-term benefits and risks, the approval provides a new option for patients who previously relied primarily on supportive care.

For families affected by this exceptionally rare neurological disorder, the availability of a targeted therapy represents an important step forward in the search for better disease management and improved outcomes.

Source

U.S. Food and Drug Administration (FDA), information regarding the approval of Zanvastro (zilganersen) for the treatment of Alexander disease, September 3, 2026.

Medical Disclaimer

This article is provided for general informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment recommendations. The information presented should not replace advice from a qualified healthcare professional. Patients, parents, and caregivers should speak with an appropriate physician or specialist about Alexander disease and whether Zanvastro may be suitable for their individual circumstances. Always review the official prescribing information and discuss potential benefits, risks, side effects, and treatment alternatives with a healthcare provider.